CR20200445A - Inhibidores de la arginasa - Google Patents
Inhibidores de la arginasaInfo
- Publication number
- CR20200445A CR20200445A CR20200445A CR20200445A CR20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- arginase inhibitors
- arg2
- arg1
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100021723 Arginase-1 Human genes 0.000 abstract 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 abstract 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 abstract 2
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 abstract 2
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638412P | 2018-03-05 | 2018-03-05 | |
| PCT/US2019/020507 WO2019173188A1 (en) | 2018-03-05 | 2019-03-04 | Arginase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200445A true CR20200445A (es) | 2021-04-27 |
Family
ID=67847429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200445A CR20200445A (es) | 2018-03-05 | 2019-03-04 | Inhibidores de la arginasa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12054500B2 (enExample) |
| EP (1) | EP3761992A4 (enExample) |
| JP (1) | JP7402167B2 (enExample) |
| KR (1) | KR102656571B1 (enExample) |
| CN (1) | CN111818928A (enExample) |
| AU (1) | AU2019229978B2 (enExample) |
| BR (1) | BR112020017604A2 (enExample) |
| CA (1) | CA3091805A1 (enExample) |
| CL (1) | CL2020002271A1 (enExample) |
| CO (1) | CO2020012060A2 (enExample) |
| CR (1) | CR20200445A (enExample) |
| EA (1) | EA202092086A1 (enExample) |
| IL (1) | IL276813B2 (enExample) |
| MX (1) | MX2020009290A (enExample) |
| MY (1) | MY205512A (enExample) |
| PE (1) | PE20210452A1 (enExample) |
| PH (1) | PH12020551352A1 (enExample) |
| SG (1) | SG11202008113RA (enExample) |
| UA (1) | UA127897C2 (enExample) |
| WO (1) | WO2019173188A1 (enExample) |
| ZA (1) | ZA202006006B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018227187A1 (en) * | 2017-06-09 | 2018-12-13 | The Regents Of The University Of California | Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| TWI828800B (zh) | 2018-11-16 | 2024-01-11 | 美商阿克思生物科學有限公司 | Arg1及/或arg2之抑制劑 |
| EP3897622B1 (en) | 2018-12-18 | 2026-01-14 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| KR20230026312A (ko) | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| EP1399467A4 (en) | 2001-05-09 | 2004-09-15 | Newbiotics Inc | PRODRUGS ACTIVATED BY PEPTIDDEFORMYLASE |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2371514T3 (es) | 2007-07-03 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | Compuestos de 3-aza-biciclo[3.3.0]octano. |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| EP2730579A1 (en) | 2008-06-17 | 2014-05-14 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20110091784A (ko) | 2008-11-26 | 2011-08-12 | 아보트 러보러터리즈 | 칼슘 채널 차단제로서의 치환된 옥타하이드로사이클로펜타［ｃ］피롤4아민 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| RU2488390C2 (ru) | 2008-12-29 | 2013-07-27 | Тартуский Университет | Ингибиторы аргиназы для лечения депрессии |
| LT2389352T (lt) | 2009-01-26 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Arginazės inhibitoriai ir naudojimo būdai |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| HRP20160305T1 (hr) * | 2010-10-26 | 2016-07-01 | Mars, Incorporated | Borati kao inhibitori arginaze |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| WO2013059437A1 (en) | 2011-10-19 | 2013-04-25 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014007831A1 (en) | 2012-07-06 | 2014-01-09 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AU2014278172B2 (en) | 2013-06-12 | 2018-08-09 | Mycovia Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2015160664A1 (en) | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| CL2014002403A1 (es) | 2014-09-11 | 2015-01-09 | Univ Pontificia Catolica Chile | Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion. |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| WO2016100555A1 (en) * | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SG11201802961PA (en) | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| JP2020502259A (ja) | 2016-11-08 | 2020-01-23 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ阻害剤併用療法 |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
-
2019
- 2019-03-04 AU AU2019229978A patent/AU2019229978B2/en active Active
- 2019-03-04 PE PE2020001352A patent/PE20210452A1/es unknown
- 2019-03-04 KR KR1020207028200A patent/KR102656571B1/ko active Active
- 2019-03-04 UA UAA202006325A patent/UA127897C2/uk unknown
- 2019-03-04 JP JP2020546139A patent/JP7402167B2/ja active Active
- 2019-03-04 MY MYPI2020004399A patent/MY205512A/en unknown
- 2019-03-04 EA EA202092086A patent/EA202092086A1/ru unknown
- 2019-03-04 US US16/978,335 patent/US12054500B2/en active Active
- 2019-03-04 WO PCT/US2019/020507 patent/WO2019173188A1/en not_active Ceased
- 2019-03-04 BR BR112020017604-4A patent/BR112020017604A2/pt unknown
- 2019-03-04 EP EP19764594.8A patent/EP3761992A4/en active Pending
- 2019-03-04 CR CR20200445A patent/CR20200445A/es unknown
- 2019-03-04 CN CN201980017421.6A patent/CN111818928A/zh active Pending
- 2019-03-04 SG SG11202008113RA patent/SG11202008113RA/en unknown
- 2019-03-04 CA CA3091805A patent/CA3091805A1/en active Pending
- 2019-03-04 IL IL276813A patent/IL276813B2/en unknown
- 2019-03-04 MX MX2020009290A patent/MX2020009290A/es unknown
-
2020
- 2020-08-28 PH PH12020551352A patent/PH12020551352A1/en unknown
- 2020-09-02 CL CL2020002271A patent/CL2020002271A1/es unknown
- 2020-09-29 CO CONC2020/0012060A patent/CO2020012060A2/es unknown
- 2020-09-29 ZA ZA2020/06006A patent/ZA202006006B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL276813A (en) | 2020-10-29 |
| CN111818928A (zh) | 2020-10-23 |
| MX2020009290A (es) | 2020-09-28 |
| AU2019229978A1 (en) | 2020-10-15 |
| UA127897C2 (uk) | 2024-02-07 |
| US12054500B2 (en) | 2024-08-06 |
| CA3091805A1 (en) | 2019-09-12 |
| IL276813B1 (en) | 2024-05-01 |
| CO2020012060A2 (es) | 2021-01-18 |
| SG11202008113RA (en) | 2020-09-29 |
| MY205512A (en) | 2024-10-24 |
| US20210002306A1 (en) | 2021-01-07 |
| BR112020017604A2 (pt) | 2020-12-22 |
| PH12020551352A1 (en) | 2021-06-21 |
| EA202092086A1 (ru) | 2021-02-09 |
| IL276813B2 (en) | 2024-09-01 |
| KR20200128117A (ko) | 2020-11-11 |
| CL2020002271A1 (es) | 2021-04-09 |
| KR102656571B1 (ko) | 2024-04-11 |
| ZA202006006B (en) | 2025-02-26 |
| AU2019229978B2 (en) | 2024-05-30 |
| WO2019173188A1 (en) | 2019-09-12 |
| EP3761992A1 (en) | 2021-01-13 |
| PE20210452A1 (es) | 2021-03-08 |
| JP7402167B2 (ja) | 2023-12-20 |
| EP3761992A4 (en) | 2021-11-24 |
| JP2021516237A (ja) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006006B (en) | Arginase inhibitors | |
| WO2020102646A3 (en) | Inhibitors of arg1 and/or arg2 | |
| MX2022011534A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa. | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| PH12021500030A1 (en) | Il-2 conjugates and methods of use thereof | |
| NZ754731A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| PH12022500003A1 (en) | Il-2 conjugates and methods of use to treat autoimmune diseases | |
| EP4248972A3 (en) | Pyridazinone compounds and uses thereof | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
| MX2023013435A (es) | Composiciones y metodos para expresar otoferlina. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| EP4248973A3 (en) | Pyridazinone compounds and uses thereof | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| PH12017502123A1 (en) | Substituted benzamides and methods of use thereof | |
| EP4663247A3 (en) | Formulations/compositions comprising a btk inhibitor | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |